Cleared Abbreviated

K013785 - UROVYSION BLADDER CANCER RECURRENCE KIT

K013785 is an FDA 510(k) clearance for UROVYSION BLADDER CANCER RECURRENCE KIT, manufactured by Vysis. The device is a Class 2 Immunology device with product code MMW cleared through the Abbreviated 510(k) pathway after a 86-day FDA review.

K013785 · Vysis · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2002
Decision
86d
Days
Class 2
Risk

K013785 is an FDA 510(k) clearance for the UROVYSION BLADDER CANCER RECURRENCE KIT. Classified as System, Test, Tumor Marker, Monitoring, Bladder (product code MMW), Class II - Special Controls.

Submitted by Vysis (Downers Grove, US). The FDA issued a Cleared decision on February 8, 2002 after a review of 86 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.6010 - the FDA immunology device framework. The Abbreviated 510(k) pathway was used, relying on FDA-recognized standards to demonstrate substantial equivalence.

Device pattern: Standards-based predicate clearance. Standards-verified equivalence. The Abbreviated pathway signals strong alignment with FDA-recognized performance standards - typically associated with lower review burden and faster clearance cycles.

View all Vysis devices

FDA 510(k) Submission Details - K013785

510(k) Number K013785 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 14, 2001
Decision Date February 08, 2002
Days to Decision 86 days
Submission Type Abbreviated
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
19d faster than avg
Panel avg: 105d · This submission: 86d
Pathway characteristics
Standards-based clearance path.

MMW Device Classification - Class 2, Special Controls

Product Code MMW System, Test, Tumor Marker, Monitoring, Bladder
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.6010
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - MMW System, Test, Tumor Marker, Monitoring, Bladder

Devices cleared under the same product code (MMW) and FDA review panel - the closest regulatory comparables to K013785.
Bladder EpiCheck DNA extraction kit, NX899090-01C, Bladder EpiCheck test kit, NX899090-02C, Bladder EpiCheck Software, NX899090-03C
K203245 · Nucleix , Ltd. · May 2023
BTA STAT TEST PRESCRIPTION HOME USE
K974845 · Bard Diagnostic Sciences,Inc. · Dec 1998
BARD BTA TRAK TEST
K971402 · Bard Diagnostic Sciences,Inc. · Apr 1998
AURA TEK FDP
K970353 · Perimmune, Inc. · Apr 1997
BARD AND BTA TEST
K964151 · Bard Diagnostic Sciences,Inc. · Apr 1997